Skip Navigation

Buttons slice

Pipeline information

Our strategy is focused on five key pillars, incorporated in our culture and in our daily work.

  • AVT02

    Biosimilar candidate
    High-concentration adalimumab
    Reference biologic
    HUMIRA®
    Therapeutic area
    Immunology

    Approved by

    • CHMP
    • Health Canada
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch

*Licenced from Biosana

HUMIRA is registered trademark of AbbVie Inc.

STELARA and SIMPONI are registered trademarks of Janssen Biotech, Inc. XOLAIR is a registered trademark of Novartis AG

PROLINA and XGEVA are registered trademarks of Amgen, Inc.

EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.